UnknownNot Applicable

Accelerated cTBS on Metabolic Dysfunction in People With Schizophrenia

China40 participantsStarted 2022-06-01

Plain-language summary

cTBS is a promising novel intervention, which has strong potential on moderating disease syndrome. However, the most effective pattern of the cTBS is still under debate. Therefore, the investigators designed this randomized controlled clinical trial to evaluate the efficacy and safety of accelerated cTBS, with 1800 stimulation per session, on intervention to metabolic side effects in individuals with schizophrenia.

Who can participate

Age range18 Years – 40 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients diagnosed with schizophrenia in accordance with DSM-5 * BMI over 24 * Accepting antipsychotics stable treatment for more then 2 months Exclusion Criteria: * Diagnosed with other mental disease in accordance with DSM-5 * Comorbid with other severe physiological disease * Used antipsychotic, antidepressants, mood stabilizer, or other psychoactive substances before * Drug or alcohol abuse * Pregnant or lactating Contraindication to rTMS

What they're measuring

Change of body weight

Timeframe: from baseline to 6 weeks

Change of body mass index

Timeframe: from baseline to 6 weeks

Trial details

NCT IDNCT05358899

SponsorCentral South University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-12-01

Contact for this trial

Renrong Wu, Prof

15874179855 wurenrong@csu.edu.cn

View on ClinicalTrials.gov More Schizophrenia trials